



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

COVID-19: Brain Effects

Ebony Dix, MD, Kamolika Roy, MD

PII: S0193-953X(22)00065-X

DOI: <https://doi.org/10.1016/j.psc.2022.07.009>

Reference: PSC 1147

To appear in: *PSYCHIATRIC CLINICS OF NORTH AMERICA*



Please cite this article as: Dix E, Roy K, COVID-19: Brain Effects, *PSYCHIATRIC CLINICS OF NORTH AMERICA* (2022), doi: <https://doi.org/10.1016/j.psc.2022.07.009>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Elsevier Inc. All rights reserved.

COVID-19: Brain Effects

Authors:

Ebony Dix, MD
Department of Psychiatry
Yale School of Medicine
1450 Chapel Street, Celentano-5
New Haven, CT 06511

Kamolika Roy, MD
University of Illinois
College of Medicine at Peoria
900 Main Street, Suite 720
Peoria, IL 61602

Corresponding Author: Ebony Dix, MD, Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. Email address: ebony.dix@yale.edu

Disclosure Statement: The authors have no financial disclosures and no conflict of interests to report.

KEYWORDS

COVID-19
SARS-CoV-2
Neuropsychiatry
Long COVID
Neuroinvasion
Neuroinflammation
Immunosenescence

KEY POINTS

- The underlying mechanisms by which SARS-CoV-2 infection effects the brain may include mechanisms related to inflammation, neuroinvasion, microvascular injury, and hypoxia.
 - Brain effects may manifest as neurologic and neuropsychiatric symptoms the acute and postacute phases of COVID-19 illness and older adults are most vulnerable to these sequelae.
 - Future research is needed to identify prevalence among other vulnerable groups, potential prognostic indicators, preventative measures, and therapeutic interventions.
-

SYNOPSIS

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus responsible for the COVID-19 pandemic, undoubtedly affects the brain. Neurologic and neuropsychiatric symptoms may manifest in the acute and post-acute phases of illness. The vulnerability of the brain with aging further increases the burden of disease in older adults who are at highest risk of complications and death from COVID-19. The mechanisms underlying the effects of COVID-19 on the brain are not fully known. Emerging evidence related to the pathogenesis and etiologies of COVID-19 brain effects are promising and may pave the way for future research and development of interventions.

INTRODUCTION

The global impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus responsible for the COVID-19 pandemic, has been particularly profound and enduring for older adults. Since the beginning of the pandemic, organizations such as the World Health Organization (WHO) and Centers for Disease Control (CDC), have warned about the elevated risk of severe illness and death due to COVID-19 in the aging population.^{1,2} Older adults, defined by the WHO as age 60 and older and by the CDC as age 65 and older, have the highest rates of morbidity and mortality following infection from COVID-19.^{2,3} Older adults are most vulnerable to adverse outcomes due to medical comorbidities and age-related physiological changes in the brain and immune system.⁴⁻⁷ While the focus here will be on the neurobiological mechanisms and increased viral susceptibility with age, it is important to recognize the influence that racial, ethnic, cultural, and socioeconomic disparities may have on worsening health outcomes in this age demographic.⁸⁻¹⁰

As ongoing research continues to unfold, there is growing evidence that COVID-19 causes pathological changes in the brain and alters cellular functioning via neuroinvasion, inflammation, microvascular injury, and hypoxia.^{4,11-15} Emerging data reveals that neuropsychiatric manifestations of COVID-19 occur in both the acute and post-acute phases of illness, and for some these symptoms persist for weeks to months after recovering from COVID-19 illness.^{15,16}

This reality has broader implications for the pathogenicity of the SARS-CoV-2 virus when considering the increased vulnerability of the brain with aging, especially in those with pre-morbid cognitive impairment and dementia.^{6-8,17-20} Epidemiological studies illustrate that acute manifestations of neurological and neuropsychiatric disease occur in up to 80% of hospitalized cases.^{13,21} In milder cases of COVID-19, these symptoms occur in the absence of typical respiratory symptoms.^{4,5,13} In older adults, postmortem histological and radiological studies reveal morphological changes in brain structure in addition to evidence of neurovascular injury within the central nervous system, suggesting potentially irreversible damage to the brain.^{5,15,22-28}

Here, we will summarize the most updated evidence underlying the proposed neuropathological and immunological processes by which COVID-19 impacts the brain. Given the rapid growth of knowledge being disseminated on this topic, we recognize that some of the proposed mechanisms have still to be fully elucidated and understood. First, we will give a brief overview of some of the known characteristics of SARS-CoV-2 that have been proposed to facilitate inflammation and neuronal injury leading to direct brain effects. We will discuss the mechanisms by which older adults may be more vulnerable to these potentially indelible effects. Then, we will highlight the neurological and neuropsychiatric symptoms that have been reported

in the literature and review the potential brain regions that may be implicated in some of the long-term sequelae. We will conclude with a summary of the current recommendations for prevention and treatment of COVID-19 in addition to a discussion of areas for future research and development.

Proposed Mechanisms: What is it and how does it infect the brain?

Similar to other strains of coronaviruses, like Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV), SARS-CoV-2 is hypothesized to enter the central nervous system (CNS) by a variety of mechanisms.^{11,15,29} The former viruses have demonstrated an ability to enter the brainstem and replicate, however, to date, there is insufficient data to support the ability of SARS-CoV-2 to do the same.^{6,30} SARS-CoV-2 is part of a family of enveloped, positive-sense, single stranded RNA viruses with viral spike (S) protein that bind to host cell entry receptors, namely, angiotensin converting-enzyme 2 (ACE2).^{4,13-15} It has been proposed that ACE2 is the key transmembrane receptor on host endothelial cells to which the S-protein binds.^{4,11,31} The fusion of cell and viral membranes is further enabled by cleavage of the S-protein attached to ACE2 by the host cell transmembrane protease, serine 2 (TMPRSS2), allowing the virus to enter cells.^{4,11,31}

While the ACE2 receptor has a wide distribution of systemic tissue expression, there is a high ACE2 receptor density in the cerebral microcirculation.¹⁵ The high burden of neurological and neuropsychiatric symptoms observed in COVID-19 suggest a particular viral tropism favoring entry through the central nervous system or the peripheral nervous system.^{14,30} SARS-CoV-2 has high affinity for ACE2 receptors in cerebral microcirculation and it has been proposed that the virus may travel via nerves innervating the respiratory tract, a primary site for

replication.^{11,15} Specifically, CNS invasion of cranial nerves via axonal transport, such as on olfactory nerve endings, have been described in the literature.^{14,15 32} Alternatively, SARS-CoV-2 may bind ACE2 receptors on olfactory epithelial cells and enter via tight junctions. In addition to viral tropism, it has been suggested that SARS-CoV-2 is capable of hematogenous spread, enabling disruption of the blood-brain-barrier (BBB) or the blood-cerebrospinal fluid barrier (B-CSFB).^{11,15} Regardless of the precise route of viral cell entry, the resulting endothelial cell damage triggers a neuroinflammatory response that is thought to be responsible for microvascular injury, leading to stroke, vasculitis, organ failure, and effects on the brain.^{9,11,15,33}

³⁴ The influx of inflammatory mediators known as “cytokine storm” and upregulation of the coagulation cascade are implicated in the activation of microglial cells.^{4,7,11,14,15} There is subsequent neurotransmission dysfunction and neuronal cell loss resulting in neurological and neuropsychiatric symptoms.^{4,7,11,14,15 35} Figure 1 is a schematic illustration summarizing the proposed mechanisms.^{4,11,13,14,33-35}

FIGURE 1. A schematic illustration summarizing the proposed mechanisms

Created with BioRender.com

Mechanisms of SARS-CoV-2 Neuroinvasion^{4,11,13,14,33-35}

1. Infection: SARS-CoV-2 respiratory droplets enter sustentacular cells of olfactory epithelium. Hematogenous transmission via ACE2 receptor binding to vascular endothelium. Endothelial damage triggers microthrombus formation, increased vWF, fibrin deposition, platelet activation). Systemic infection leads to oxidative stress, hypoxia, and hyperinflammatory state.

2. Neuronal transmission: Neuronal injury and infection trigger recruitment and activation of immune cells including glial cells, astrocytes, macrophages and T-lymphocytes. SARS-CoV-2 neuroinvasion causes neuroinflammation by way of cytokine storm (production and release of TNF-alpha, IL-6, IL-10, IL-1 β) that directly induces microglia activation and indirectly triggers coagulation cascade (which leads to further microglia activation).

3. CNS pathophysiology: Microglia activation leads to increased kynurenine production, which increases quinolinic acid (increases glutamate and upregulates NMDA receptors) and depletes neurotransmitters (serotonin, dopamine, norepinephrine). Altered neurotransmission and excitotoxicity by increased glutamate and hypoxic injury contribute to neuronal dysfunction and cell death. Demyelination (due to oligodendroglial cell death), neuronal excitotoxicity, hypoxia and synaptic alterations. Cytokine storm leads to neuroinflammation, increased vascular permeability, dysfunction of blood brain and blood-CSF barriers, and subsequent neurodegeneration. Coagulation cascade and elevation of vWF lead to thrombotic events. Hypercoagulation increases D-dimer, fibrinogen and thrombus formation.

ACE2; von Willebrand factor, vWF; N-methyl-D-aspartate, NMDA; TNF, tumor necrosis factor; IL, interleukin

Neurologic and Neuropsychiatric Manifestations

During the COVID-19 pandemic, nomenclature has emerged to identify neurologic and neuropsychiatric symptoms as they related to specific periods of time during COVID-19 illness. Acute symptoms have been reported in the literature to last up to approximately 4 weeks and

include delirium, encephalitis, stroke, and psychiatric disorders.^{13,20,33,34,36,37} For the purposes of this paper, the term post-acute will refer to chronic or long-term neuropsychiatric symptoms lasting any time beyond 4 weeks after acute infection. In the published literature to date, many refer to long-term neuropsychiatric symptoms that continue for 12 weeks or more, after one has recovered from COVID-19 illness.³⁸ The term “long COVID” is gaining recognition as a way to identify some of the symptoms that have lasting effects on individuals long after their recovery from acute infection.^{15,38,39} There is little understood as of the writing of this paper the exact etiologies or risk factors for this condition, especially since symptom development does not correlate with severity of COVID-19 illness.^{15,38,39} The constellation of symptoms associated with long COVID are also sometimes referred to as the post-acute sequelae of COVID-19 (PASC) and may be used interchangeably in this discussion.⁴⁰⁻⁴² The phenomenon of long COVID is unique in that it appears to represent a protracted course of neurologic and neuropsychiatric sequelae across all age groups. Long COVID has been reported to include a wide range of symptoms including dyspnea, fatigue, sleep disturbances and neuropsychiatric symptoms such as headache, memory loss, concentration, and changes in mood.^{2,13-16,38,40} One proposed mechanism for the lasting brain effects after recovering from acute illness is that SARS-CoV-2 remains dormant in neurons and the delayed effect of neuroinflammation leads to demyelination and neurodegeneration.⁴³

Due to the increasing prevalence of these symptoms and impact on daily functioning, there is still much to be learned and understood about what causes these sequelae and how they may be prevented or reversed.^{32,33,38,40} Broadly, acute effects of viral infection can include acute stroke, neuromuscular dysfunction, demyelinating disorders, encephalopathy, confusion, emotional disturbances and psychosis. Acute neurological events in individuals over age 50 most

commonly include cerebrovascular events followed by anosmia/hyposmia, hypogeusia and those aged 65 and older more commonly present with confusion and stroke symptoms.^{22,44-46}

Delirium is often multifactorial in nature and in older adults, it may be the first acute presenting symptom of COVID-19, creating a diagnostic challenge and possible delays in care. There is some evidence that suggests individuals who experienced delirium during their acute illness were likely to be affected by PASC.⁴¹

Some of the postacute neuropsychiatric sequelae commonly noted in the literature include depression, anxiety, cognitive difficulties including memory impairment, inattention, executive dysfunction, concentration difficulty as well as headache.^{3,22,43} In those hospitalized due to COVID-19, anxiety, depression, sleep impairment and posttraumatic disorder comprised the longstanding PASC.³³

Table 1. Neurologic and Neuropsychiatric Manifestations

Neurological symptoms

- CNS effects: anosmia, ageusia, stroke - hemorrhagic and ischemic, CNS vasculitis, acute inflammation of brain, spinal cord, meninges leading to encephalitis or encephalopathy.⁴⁷
- PNS effects: neuromuscular disorders like Guillain-Barre syndrome, Miller Fisher variant, Bell's palsy and other demyelinating neuropathies, epilepsy (direct vs indirect cause; secondary to cytokine storm). Nonspecific neurological manifestations include headache, fatigue and myalgias.^{30,47}

Neuropsychiatric symptoms

- Neuropsychiatric symptoms secondary to excitotoxicity and hypoxic injury and differ depending on the Brodmann area involved.
- Acute psychiatric symptoms include depression, anxiety, insomnia, memory impairment, psychosis and delirium/encephalopathy (acute confusion and agitation).⁴⁷ Many of these may persist as late neuropsychiatric sequelae including depression, suicidal behavior, anxiety, psychosis, seizures, insomnia, fatigue, posttraumatic stress, attention deficits, memory impairment and irritability. Encephalitis lethargica (caused by 1918 influenza pandemic) and limbic encephalitis.³⁴

What does neuroimaging research reveal about brain changes due to COVID-19?

The literature concerning the effects of the SARS-CoV2 virus on the brain continues to expand and there is no exception when reviewing neuroimaging research available on this topic. As we enter the third year of the pandemic, the data collected and analyzed has also evolved. Earlier radiological studies aimed at characterizing abnormal neuroimaging findings on MRI and CT scans in COVID-19 infected individuals including cerebral microhemorrhages, acute spontaneous intracranial hemorrhage, acute and subacute infarcts and encephalitis or encephalopathy.⁴⁸ Subsequent systematic reviews with meta-analysis of MRI, PET and CT studies have revealed specific brain regions that may be structurally and functionally affected in COVID-19 such as olfactory cortex extending to prefrontal and limbic regions²⁸.

Many of these neuroimaging studies have suggested COVID-19 brain-related pathologies in the elderly (aged > 60 years old) in the brainstem and frontotemporal regions including

cerebrovascular injury, hypoperfusion, evidence of inflammation and cellular damage along white matter tracts.^{22,44-46} Such investigations have identified risk factors that contribute to severity of COVID-19 illness such as pre-existing neurological illness, psychiatric illness, sleep disturbance, immunosenescence and hyperinflammatory states with age. However, investigations thus far have been unable to isolate the direct impact of pathogenicity of SARS-COV infection in the brain.

More recently, the UK Biobank COVID-19 re-imaging case-control study has been the first and largest of its kind to elucidate statistically significant longitudinal changes in the brain due to SARS-COV infection by comparing neuroimaging scans from affected individuals both pre- and post- COVID-19 infection.⁵ Early evidence from this study suggests greater reduction in global brain size, the possibility of the left cerebral hemisphere being more strongly associated with SARS-CoV2 infection and longitudinal limbic olfactory brain changes involving functionally-connected regions of anterior cingulate cortex, orbitofrontal cortex, amygdala, hippocampus and parahippocampal gyrus.⁵

Primary brain regions demonstrating altered structure or function on neuroimaging include olfactory cortex and subsequent projection areas like orbitofrontal cortex, amygdala, insula, entorhinal cortex and hippocampus.²⁸ Neuroimaging findings involving brain regions implicated in COVID-19 infection are summarized in Table 2. The table summarizes findings derived from a review of case series, cohort studies and systematic reviews.¹³

TABLE 2. Neuroimaging Findings on the brain regions implicated in SARS-CoV-2 infection

Considerations for COVID-19 in persons with dementia (PwD)

Early during the COVID-19 pandemic, older adults were identified as the most vulnerable population to SARS-CoV2 infection due to increased burden of pre-existing medical comorbidities, frailty, and age-related immune system dysfunction known as immunosenescence.^{4,49} Further review of literature on effects of COVID-19 in older individuals reveals an atypical course of symptom presentation in which may include no fever or low-grade fever and the absence of common respiratory symptoms such as dyspnea and cough, which may lead to delayed diagnosis of COVID-19 in the geriatric population.³

Atypical symptom presentation is also common in persons with dementia who contract COVID-19 and may manifest as exacerbation of cognitive decline, impairment in activities of daily living or worsening behavioral and psychological symptoms of dementia (BPSD). However, delirium is commonly the first presenting symptom in persons with dementia with acute SARS-CoV2 infection.³⁴ Using a validated measurement tool for detecting delirium like the Confusion Assessment Method (CAM) is recommended, but there is currently no existing equivalent tool for detecting long COVID or PACS.

Underlying cognitive impairment is known to be associated with higher rates of delirium due to medical illness and it is well-known that delirium may be protracted in individuals with dementia. Therefore, not surprisingly, persons with mild cognitive impairment or dementia who contract the SARS-CoV2 virus are at greater risk of severe illness and are more vulnerable to long-term neuropsychiatric sequelae.^{22,34,44-46} Specifically, persons with dementia due to

underlying neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, may experience an exacerbation of pre-existing BPSD due to COVID-19, therefore monitoring for changes can be essential for early detection of acute infection. Symptom overlap with BPSD and long-term neuropsychiatric sequelae, such as agitation, apathy and aberrant motor activity, presents a challenge to those caring for persons with dementia.³⁰

Treatment Recommendations

There is currently limited published data to support the use of any specific agent for the treatment or prevention of neuropsychiatric sequelae of COVID-19. Multiple national organizations such as the WHO and CDC, and The National Institutes of Health, have highly recommended vaccination for all eligible older adults to prevent and reduce the risk of severe illness.² As of the time of this writing, The National Institutes of Health COVID-19 Treatment Guidelines Panel continue to update their website regarding the therapeutic management of hospitalized and non-hospitalized adults. The guidance on clinical management of COVID-19 inpatients changes rapidly as we gain better understanding of the virus. Current knowledge about SARS-CoV-2 has enabled the use of therapeutic agents such as antivirals, like remdesivir and immunomodulators, such as corticosteroids and monoclonal antibodies.^{31,49} There is some hope that an improved understanding about the mechanisms of these drugs will inspire future research and development of immunotherapeutic agents that can potentially mitigate the acute and postacute brain effects of COVID-19. In the absence of a more novel approach, for now, the use of pre-existing evidence-based treatments and standards of care will continue to be employed for treating the neurologic and neuropsychiatric symptoms that emerge from COVID-19. For the treatment of delirium, there is no clinical consensus, however there is a growing body of data

that supports the efficacy of using low-dose neuroleptics and alpha-adrenergic blockers for managing symptoms.^{2,50,51} However, the ever present challenge in the pharmacological treatment of delirium in older adults with COVID-19 will be to carefully avoid adverse events due to drug interactions, or medical contraindications and to weigh the risks versus benefits of those agents known to be potentially harmful in older adults.⁵²

SUMMARY

In conclusion, the long-term effects of COVID-19 on the brain, has left an indelible imprint on the global community. Whether acute or postacute, brain effects have impacted individuals across all age groups, irrespective of the severity of COVID-19 illness. The knowledge regarding the neuropathology of the virus suggests that by way of neuroinvasion and hyperinflammation, neurologic and neuropsychiatric symptoms may emerge and persist for an extended period, well after one has recovered from COVID-19. Data also suggest that a major risk factor for lasting brain effects is age, and the neuropsychiatric sequelae present a greater burden on older adults, especially those with pre-morbid cognitive impairment.^{8,18,20,33,46} Detecting delirium or changes in baseline behavior in older adults may be an early key finding in the acute phase of illness, given the propensity for atypical COVID-19 presentations in this age group.

As the current understanding of the neurochemical and immunological processes underlying the brain effects of COVID-19 continues to evolve, lessons learned up to this point during the pandemic will undoubtedly pave the way for future research and innovation. By applying the current knowledge about how the brain and immune system respond to acute COVID-19 infection, we will hopefully soon identify other risks factors and prognostic

indicators in a variety of other populations. Areas of need for further research include epidemiological studies that identify the true prevalence and incidence of long COVID across the life span and any potentially irreversible sequelae. It will be equally important to ensure such studies not only look at all age groups and at people who have both in vaccinated and unvaccinated, but also at individuals of diverse backgrounds and geographical regions. Given the existing healthcare disparities related to race, ethnicity, and socioeconomic status, the pandemic presents an opportunity for a critical look at how biopsychosocial factors might influence the development of future vaccines and immunotherapies.²

.....

Clinics Care Points Evidence based pearls and pitfalls relevant to the point of care)

- *SARS-CoV-2 infection causes acute and postacute neurologic and neuropsychiatric symptoms, some of which persist for weeks to months and is known as long COVID or PACS*
- *Neuropathological mechanisms have been hypothesized to trigger neuroinflammation, causing downstream effects on neurotransmitters, leading to a myriad of symptoms.*
- *Increased vulnerability of the brain with aging places older adults, especially those with cognitive impairment, at increased risk for neuropsychiatric sequelae from COVID-19.*
- *Persons with dementia may have atypical presentations of COVID-19, which lead to delays in diagnosis and increases risk of severe illness and death.*
- *Persons with dementia are at an increased risk of persistent post-acute neuropsychiatric sequelae, which may be difficult to differentiate from worsening dementia.*

- *In caring for persons with dementia, monitoring for changes in baseline mentation (delirium) or worsening of pre-existing behavioral disturbances, may be the earliest way to detect acute COVID-19 infection.*
- *A better understanding of the mechanisms by which COVID-19 effects the brain will pave the way for future research and development of potential preventative and therapeutic approaches.*

References

1. De Pue S, Gillebert C, Dierckx E, Vanderhasselt MA, De Raedt R, Van den Bussche E. The impact of the COVID-19 pandemic on wellbeing and cognitive functioning of older adults. *Sci Rep*. Feb 25 2021;11(1):4636. doi:10.1038/s41598-021-84127-7
2. World Health Organization. Regional Office for the Western P. *Guidance on COVID-19 for the care of older people and people living in long-term care facilities, other non-acute care facilities and home care*. 2020. 2020-04-01. <http://iris.wpro.who.int/handle/10665.1/14500>
3. Bansod S, Ahirwar AK, Sakarde A, et al. COVID-19 and geriatric population: from pathophysiology to clinical perspectives. *Horm Mol Biol Clin Investig*. Feb 4 2021;42(1):87-98. doi:10.1515/hmbci-2020-0053
4. Chen Y, Klein SL, Garibaldi BT, et al. Aging in COVID-19: Vulnerability, immunity and intervention. *Ageing Res Rev*. Jan 2021;65:101205. doi:10.1016/j.arr.2020.101205
5. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature*. Mar 7 2022;doi:10.1038/s41586-022-04569-5
6. Mainali S, Darsie ME. Neurologic and Neuroscientific Evidence in Aged COVID-19 Patients. *Front Aging Neurosci*. 2021;13:648662. doi:10.3389/fnagi.2021.648662
7. Perrotta F, Corbi G, Mazzeo G, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. *Aging Clin Exp Res*. Aug 2020;32(8):1599-1608. doi:10.1007/s40520-020-01631-y
8. Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. *EClinicalMedicine*. Sep 2021;39:101044. doi:10.1016/j.eclinm.2021.101044
9. Wang Z, Zheutlin A, Kao YH, et al. Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. *BMJ Open*. Oct 26 2020;10(10):e040441. doi:10.1136/bmjopen-2020-040441

10. Willey B, Mimmack K, Gagliardi G, et al. Racial and socioeconomic status differences in stress, posttraumatic growth, and mental health in an older adult cohort during the COVID-19 pandemic. *EClinicalMedicine*. Mar 2022;45:101343. doi:10.1016/j.eclinm.2022.101343
11. Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. *JAMA Psychiatry*. Jun 1 2021;78(6):682-683. doi:10.1001/jamapsychiatry.2021.0500
12. Butler M, Bano F, Calcia M, et al. Clozapine prescribing in COVID-19 positive medical inpatients: a case series. *Ther Adv Psychopharmacol*. 2020;10:2045125320959560. doi:10.1177/2045125320959560
13. Han Y, Yuan K, Wang Z, et al. Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. *Transl Psychiatry*. Sep 30 2021;11(1):499. doi:10.1038/s41398-021-01629-8
14. Johansson A, Mohamed MS, Moulin TC, Schiöth HB. Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms. *J Neuroimmunol*. Sep 15 2021;358:577658. doi:10.1016/j.jneuroim.2021.577658
15. Bauer L, Laksono BM, de Vrij FMS, Kushner SA, Harschnitz O, van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. *Trends Neurosci*. Mar 3 2022;doi:10.1016/j.tins.2022.02.006
16. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *The Lancet Psychiatry*. 2021;8(5):416-427. doi:10.1016/s2215-0366(21)00084-5
17. Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. *Neurocrit Care*. Jun 2021;34(3):1062-1071. doi:10.1007/s12028-020-01049-4
18. Lebrasseur A, Fortin-Bédard N, Lettre J, et al. Impact of the COVID-19 Pandemic on Older Adults: Rapid Review. *JMIR Aging*. Apr 12 2021;4(2):e26474. doi:10.2196/26474
19. Nersesjan V, Fonsmark L, Christensen RHB, et al. Neuropsychiatric and Cognitive Outcomes in Patients 6 Months After COVID-19 Requiring Hospitalization Compared With Matched Control Patients Hospitalized for Non-COVID-19 Illness. *JAMA Psychiatry*. Mar 23 2022;doi:10.1001/jamapsychiatry.2022.0284
20. Simonetti A, Pais C, Jones M, et al. Neuropsychiatric Symptoms in Elderly With Dementia During COVID-19 Pandemic: Definition, Treatment, and Future Directions. *Front Psychiatry*. 2020;11:579842. doi:10.3389/fpsy.2020.579842
21. Chou SH, Beghi E, Helbok R, et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. *JAMA Netw Open*. May 3 2021;4(5):e2112131. doi:10.1001/jamanetworkopen.2021.12131
22. Frontera JA, Yang D, Lewis A, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. *J Neurol Sci*. Jul 15 2021;426:117486. doi:10.1016/j.jns.2021.117486
23. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. Jan 16 2021;397(10270):220-232. doi:10.1016/s0140-6736(20)32656-8
24. Kremer S, Gerevini S, Ramos A, et al. Neuroimaging in patients with COVID-19: a neuroradiology expert group consensus. *Eur Radiol*. Jan 19 2022;1-10. doi:10.1007/s00330-021-08499-0

25. Kremer S, Lersy F, Anheim M, et al. Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study. *Neurology*. Sep 29 2020;95(13):e1868-e1882. doi:10.1212/wnl.00000000000010112
26. Kremer S, Lersy F, de Sèze J, et al. Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study. *Radiology*. Nov 2020;297(2):E242-e251. doi:10.1148/radiol.2020202222
27. Lersy F, Benotmane I, Helms J, et al. Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. *J Infect Dis*. Feb 24 2021;223(4):600-609. doi:10.1093/infdis/jiaa745
28. Najt P, Richards HL, Fortune DG. Brain imaging in patients with COVID-19: A systematic review. *Brain Behav Immun Health*. Oct 2021;16:100290. doi:10.1016/j.bbih.2021.100290
29. Roy D, Ghosh R, Dubey S, Dubey MJ, Benito-León J, Kanti Ray B. Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic. *Can J Neurol Sci*. Jan 2021;48(1):9-24. doi:10.1017/cjn.2020.173
30. Manolis TA, Apostolopoulos EJ, Manolis AA, Melita H, Manolis AS. COVID-19 Infection: A Neuropsychiatric Perspective. *J Neuropsychiatry Clin Neurosci*. Fall 2021;33(4):266-279. doi:10.1176/appi.neuropsych.20110277
31. V'Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. *Nat Rev Microbiol*. Mar 2021;19(3):155-170. doi:10.1038/s41579-020-00468-6
32. Qin Y, Wu J, Chen T, et al. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. *J Clin Invest*. Apr 15 2021;131(8)doi:10.1172/jci147329
33. Alonso-Lana S, Marquié M, Ruiz A, Boada M. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. *Front Aging Neurosci*. 2020;12:588872. doi:10.3389/fnagi.2020.588872
34. Nakamura ZM, Nash RP, Laughon SL, Rosenstein DL. Neuropsychiatric Complications of COVID-19. *Curr Psychiatry Rep*. Mar 16 2021;23(5):25. doi:10.1007/s11920-021-01237-9
35. Sawlani V, Scotton S, Nader K, et al. COVID-19-related intracranial imaging findings: a large single-centre experience. *Clin Radiol*. Feb 2021;76(2):108-116. doi:10.1016/j.crad.2020.09.002
36. Burchill E, Rogers JP, Needham D, Lang AE, Nicholson TR. Neuropsychiatric disorders and COVID-19. *Lancet Psychiatry*. Jul 2021;8(7):564-565. doi:10.1016/s2215-0366(21)00178-4
37. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric syndromes and COVID-19 - Authors' reply. *Lancet Psychiatry*. Aug 2020;7(8):664-665. doi:10.1016/s2215-0366(20)30304-7
38. (2022).
39. Butler M, Cross B, Hafeez D, et al. Emerging Knowledge of the Neurobiology of COVID-19. *Psychiatr Clin North Am*. Mar 2022;45(1):29-43. doi:10.1016/j.psc.2021.11.001
40. The Lancet N. Long COVID: understanding the neurological effects. *Lancet Neurol*. Apr 2021;20(4):247. doi:10.1016/s1474-4422(21)00059-4
41. Cray HV, Vahia IV. Two Years of COVID-19: Understanding Impact and Implications for the Mental Health of Older Adults. *Am J Geriatr Psychiatry*. Apr 2022;30(4):444-447. doi:10.1016/j.jagp.2022.02.005

42. Tabacof L, Tosto-Mancuso J, Wood J, et al. Post-acute COVID-19 Syndrome Negatively Impacts Physical Function, Cognitive Function, Health-Related Quality of Life, and Participation. *Am J Phys Med Rehabil*. Jan 1 2022;101(1):48-52. doi:10.1097/phm.0000000000001910
43. Kumar S, Veldhuis A, Malhotra T. Neuropsychiatric and Cognitive Sequelae of COVID-19. *Front Psychol*. 2021;12:577529. doi:10.3389/fpsyg.2021.577529
44. Frontera JA, Melmed K, Fang T, et al. Toxic Metabolic Encephalopathy in Hospitalized Patients with COVID-19. *Neurocrit Care*. Dec 2021;35(3):693-706. doi:10.1007/s12028-021-01220-5
45. Beghi E, Giussani G, Westenberg E, et al. Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions. *J Neurol*. Oct 21 2021;1-10. doi:10.1007/s00415-021-10848-4
46. Frontera JA, Wisniewski T. Editorial: Neurological and Neuroscientific Evidence in Aged COVID-19 Patients. *Front Aging Neurosci*. 2021;13:774318. doi:10.3389/fnagi.2021.774318
47. Slooter AJC, Otte WM, Devlin JW, et al. Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies. *Intensive Care Med*. May 2020;46(5):1020-1022. doi:10.1007/s00134-019-05907-4
48. Choi Y, Lee MK. Neuroimaging findings of brain MRI and CT in patients with COVID-19: A systematic review and meta-analysis. *Eur J Radiol*. Dec 2020;133:109393. doi:10.1016/j.ejrad.2020.109393
49. van Eijk LE, Binkhorst M, Bourgonje AR, et al. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. *J Pathol*. Jul 2021;254(4):307-331. doi:10.1002/path.5642
50. Baller EB, Hogan CS, Fusunyan MA, et al. Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19. *Psychosomatics*. Nov-Dec 2020;61(6):585-596. doi:10.1016/j.psych.2020.05.013
51. Velásquez-Tirado JD, Trzepacz PT, Franco JG. Etiologies of Delirium in Consecutive COVID-19 Inpatients and the Relationship Between Severity of Delirium and COVID-19 in a Prospective Study With Follow-Up. *J Neuropsychiatry Clin Neurosci*. Summer 2021;33(3):210-218. doi:10.1176/appi.neuropsych.20100251
52. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. Apr 2019;67(4):674-694. doi:10.1111/jgs.15767

	ACUTE COVID-19 ILLNESS	POST-ACUTE COVID-19 ILLNESS
NEUROLOGIC SYMPTOMS	Anosmia, hyposmia Hypogeusia, dysgeusia Encephalitis Stroke Neuromuscular dysfunction Demyelinating disorders Acute encephalopathy*	Anosmia Encephalopathy Encephalitis Stroke Headache Neurodegeneration Demyelination Neuropathy
NEUROPSYCHIATRIC SYMPTOMS	Psychiatric Disorders Mood disorders Catatonia Anxiety Insomnia Psychosis Neurocognitive Disorders Delirium* Major/minor neurocognitive disorder	Psychiatric Disorders Mood disorders Anxiety Insomnia Psychosis Posttraumatic stress disorder Neurocognitive Disorders Cognitive impairment - memory deficits, inattention, executive dysfunction

*Interchangeable per updated nomenclature guidelines, in Slooter et al.

TABLE 2. Neuroimaging findings on brain regions implicated in SARS-CoV2 infection

	<u>Brain region</u>	<u>Imaging findings</u>	<u>Study</u>	<u>Imaging modality</u>	<u>Study Design</u>
Cortical regions	Anterior cingulate cortex (PFC)	Impairments in connectivity and signal intensity (fMRI), FDG hypometabolism (PET)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Orbitofrontal cortex (PFC)	Greater reduction in grey matter thickness and tissue-contrast (MRI)	Douaud et al 2022	MRI, fMRI	Case control cohort study
		FDG hypometabolism (PET)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Olfactory cortex (limbic)	Greater changes in markers of tissue damage (fMRI)	Douaud et al 2022	MRI, fMRI	Case control cohort study
		Altered cortical volume, thickness and hypometabolism	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Insula (limbic)	Low grey matter volume/reduced cortical thickness (MRI)	Douaud et al 2022	MRI, fMRI	Case control cohort study
		FDG hypometabolism (PET)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Superior temporal gyrus (limbic)	Reduced cortical thickness	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Parahippocampal gyrus (limbic)	Greater reduction in grey matter thickness and tissue-contrast	Douaud et al 2022	MRI, fMRI	Case control cohort study
		FDG hypometabolism (PET)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
Subcortical regions	Entorhinal cortex	Greater changes in markers of tissue damage (fMRI)	Douaud et al 2022	MRI, fMRI	Case control cohort study
	Thalamus	FDG hypometabolism (PET)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Amygdala (limbic)	FDG hypometabolism (PET)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Hippocampus (limbic)	Low grey matter volume/reduced cortical thickness, decreased cerebral blood flow (MRI)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Corpus callosum	Increased diffusivity indicating tissue damage, white matter abnormalities due to microhemorrhage (MRI)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
	Brainstem	White matter and volume abnormalities due to microhemorrhage (MRI)	Najt et al 2021	MRI, PET, CT	Systematic review and meta-analysis
		FDG hypometabolism (PET)			

